Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 6Stomach Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1HER2 1Gastric Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

Carboplatin 177Radiotherapy 139Cisplatin 110Pemetrexed 102Docetaxel 93Paclitaxel 92Gemcitabine 78Erlotinib Hydrochloride 73Magnetic Resonance Spectroscopy 72Radiosurgery 67Bevacizumab 65pembrolizumab 64Etoposide 60Blood Specimen Collection 60durvalumab 53Specimen Handling 48Nivolumab 48Surveys and Questionnaires 47Drug Therapy 41Standard of Care 35Radiation 33osimertinib 32atezolizumab 32Surgical Procedures, Operative 30Topotecan 29Irinotecan 29Gefitinib 29Educational Status 29Early Intervention, Educational 29Biopsy 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lung Neoplasms × disitamab vedotin × Clear all
NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting
58 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡